Halozyme Therapeutics, Inc. (NASDAQ:HALO) is Steamboat Capital Partners LLC's 8th Largest Position

Steamboat Capital Partners LLC grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 43.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 249,751 shares of the biopharmaceutical company's stock after purchasing an additional 75,890 shares during the quarter. Halozyme Therapeutics comprises approximately 3.7% of Steamboat Capital Partners LLC's investment portfolio, making the stock its 8th largest position. Steamboat Capital Partners LLC owned approximately 0.20% of Halozyme Therapeutics worth $11,941,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HALO. Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $29,000. CBIZ Investment Advisory Services LLC bought a new stake in Halozyme Therapeutics in the fourth quarter worth approximately $29,000. Smartleaf Asset Management LLC lifted its stake in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares during the period. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust boosted its holdings in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the transaction, the director now owns 33,108 shares in the company, valued at approximately $2,120,567.40. This represents a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,126,499.68. This trade represents a 0.97% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 21,697 shares of company stock valued at $1,276,552. 2.40% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on HALO shares. Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $73.00 to $62.00 in a research note on Wednesday, May 14th. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $61.90.

Halozyme Therapeutics Stock Up 1.0%

Shares of NASDAQ HALO traded up $0.52 during mid-day trading on Friday, reaching $54.27. 352,831 shares of the company's stock traded hands, compared to its average volume of 1,825,572. The stock has a market cap of $6.69 billion, a P/E ratio of 15.82, a PEG ratio of 0.42 and a beta of 1.26. The business has a 50-day simple moving average of $60.04 and a 200 day simple moving average of $55.89. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.50. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. The business had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company's quarterly revenue was up 35.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.79 EPS. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.